Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Arcturus Therapeutics Holdings Inc. (ARCT)

24.59   -0.72 (-2.84%) 01-21 18:02
Open: 24.99 Pre. Close: 25.31
High: 26.25 Low: 24.5883
Volume: 516,492 Market Cap: 648M
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the treatment of liver and respiratory care diseases. Its preclinical drug discovery and development programs include LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene. The company owns LUNAR and nucleic acid technologies that are covered by a patent portfolio of 209 patents and patent applications, issued in the United States and other countries. It has collaboration partnerships with Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for certain rare disease targets; Millennium Pharmaceuticals, Inc. (Takeda) to develop a nucleic acid-based therapeutic candidate for the treatment of nonalcoholic steatohepatitis; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus infection; CureVac AG to develop mRNA therapeutic and vaccine candidates; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 26.289 - 26.473 26.473 - 26.614
Low: 24.128 - 24.368 24.368 - 24.551
Close: 24.262 - 24.583 24.583 - 24.829

Technical analysis

as of: 2022-01-21 4:24:49 PM
Overall:       
Stoxline posted a SELL today, upgraded from strong sell. Downward movement continues, but could change at any time.
Target: Six months: 46.16     One year: 56.94
Support: Support1: 24.59    Support2: 20.46
Resistance: Resistance1: 39.52    Resistance2: 48.75
Pivot: 32.47
Moving Average: MA(5): 27.45     MA(20): 34.19
MA(100): 42.03     MA(250): 42.63
MACD: MACD(12,26): -3.41     Signal(9): -2.24
Stochastic oscillator: %K(14,3): 1.12     %D(3): 4.47
RSI: RSI(14): 27.97
52-week: High: 89.18  Low: 24.59  Change(%): -63.4
Average Vol(K): 3-Month: 618  10-Days: 483

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and BEARISH in mid-long term.
ARCT has closed above bottom band by 6.1%. Bollinger Bands are 57.8% wider than normal. The large width of the bands suggest high volatility as compared to Arcturus Therapeutics Holdings Inc.'s normal range. The bands have been in this wide range for 1 bars. This is a sign that the current trend might continue.

Headline News

Wed, 12 Jan 2022
$12.90 Million in Sales Expected for Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) This Quarter - MarketBeat

Wed, 05 Jan 2022
Arcturus Therapeutics Holdings Inc. Expected to Earn FY2026 Earnings of $62.40 Per Share (NASDAQ:ARCT) - MarketBeat

Tue, 04 Jan 2022
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat

Sat, 25 Dec 2021
Arcturus Therapeutics Holdings (NASDAQ:ARCT) Has Debt But No Earnings; Should You Worry? - Nasdaq

Thu, 18 Nov 2021
Is Arcturus Therapeutics Holdings Inc (ARCT) a Good Buy in the Biotechnology Industry? - InvestorsObserver

Mon, 08 Nov 2021
Arcturus Therapeutics Announces Third Quarter 2021 Financial Update and Pipeline Progress - Business Wire

Financial Analysis

Growth
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Underperform Price to Earnings: Underperform
Return on Equity: Underperform Debt to Equity: Outperform
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 26
Shares Float (M) 23
% Held by Insiders 13.91
% Held by Institutions 70.06
Shares Short (K) 2,350
Shares Short P. Month (K) 2,500

Stock Financials

EPS -7.550
EPS Est This Year
EPS Est Next Year
Book Value (p.s.) 9.830
Profit Margin
Operating Margin -2229.80
Return on Assets (ttm) -32.4
Return on Equity (ttm) -75.3
Qtrly Rev. Growth 4.5
Gross Profit (p.s.) -1.833
Sales Per Share 0.334
EBITDA (p.s.) -7.403
Qtrly Earnings Growth
Operating Cash Flow (M) -99
Levered Free Cash Flow (M) -30

Stock Valuations

PE Ratio -3.26
PEG Ratio
Price to Book value 2.50
Price to Sales 73.66
Price to Cash Flow

Stock Dividends

Dividend
Forward Dividend
Dividend Yield
Dividend Pay Date 2017-11-15
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
Stock Chart
stoxline_lite
Stoxline Lite
stoxline_pro
Stoxline Pro
Option_Calculator
Option Calculator
(c) 2006-2020 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.